Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies have shown that androgen receptor (AR) signaling activation may be one of the mechanisms, and targeting AR showed some promising results in AR-positive triple-negative breast cancer.
|
31434793 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the characteristics, clinical behaviour and role of biomarkers (androgen receptor (AR), oestrogen receptor beta (ERβ) and p53) in metastatic TNBC.
|
31563883 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.
|
30783520 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients' prognosis.
|
31319547 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A poor DFS was observed for AR+/FOXA1+ tumors compared to other TNBCs (<i>p</i> = 0.0117).
|
31540486 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
|
31106385 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined in vivo effects of JQ1 in a xenograft model of AR expressing TNBC.
|
31527644 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of grade 3 tumors was lower among AR-positive TNBC tumors compared to AR-negative tumors (40 vs 86.4%, p<0.001).
|
30570854 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the diagnostic value of estrogen receptor, progesterone receptor, human epidermal growth factor receptor, thyroid transcription factor-1 (TTF1), Napsin A, mammaglobin, gross cystic disease fluid protein 15 (GCDFP15), Sry-related HMg-Box gene 10 (SOX10), GATA-binding protein 3 (GATA3), and androgen receptor in a series of 207 TNBC and 152 primary lung adenocarcinomas (LA).
|
30628926 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bivariate fit analysis demonstrated that QNBC (n = 224) significantly (P < .03) correlated with younger aged patients at initial biopsy compared to AR positive TNBC patients (n = 51).
|
30594038 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
|
30805773 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified Chk1 as a putative drug target in AR-positive TNBCs.
|
30352905 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to determine if the imaging features of TNBCs differ by AR (androgen receptor) status, which is a surrogate immunohistochemical (IHC) marker for the chemoresistant LAR subtype of TNBC.
|
31005169 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recognition of these tumour subsets has opened potential avenues for therapies exploiting the AR pathway in triple negative breast carcinoma (TNBC).
|
30425121 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The androgen receptor (AR) is proposed as a therapeutic target for AR-positive advanced triple-negative breast cancer.
|
29713287 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting androgen receptor (AR) in TNBC is thought to be a promising approach.
|
29964098 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling.
|
30279965 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early data from clinical trials evaluating AR antagonists in invasive/metastatic triple-negative breast cancer suggest that some patients may benefit from androgen blockade.
|
29489512 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies have shown it to antagonize estrogen receptor alpha (ERα) DNA binding, thereby preventing pro-proliferative gene transcription; whilst others have demonstrated AR to take on the mantle of a pseudo ERα particularly in the setting of triple negative breast cancer.
|
30416486 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent efforts aimed at molecular characterisation of TNBCs have revealed various emerging therapeutic targets including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, androgen receptor and epigenetic proteins.
|
29202431 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
|
29940524 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
|
29880907 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC.
|
29373071 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, AR stimulates cellular proliferation in triple negative breast cancer (ERα -, PgR -, and HER-2-Neu -).
|
30210453 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
|
29484502 |
2018 |